Inclusion Criteria:
  1. Age > 14 years old；
  2. Warfarin anticoagulant therapy is required for at least 3 months；
  3. The genotype of patient VKORC1 is non-AA, CYP2C9 genotype is non*1/*1； the patients who are followed up, regularly monitored for INR and willing to provide peripheral blood for DNA extraction and genetic testing；
  4. The patient or family members can understand the research plan and will participate in this study and provide a written informed consent；
Exclusion Criteria:
  1. Severe liver dysfunction (ChildPugh ≥ 10);
  2. Severe infection, respiratory failure;
  3. Severe heart failure ( NYHA ≥ IV);
  4. Severe renal insufficiency (Ccr ≤ 20ml / min);
  5. Cancer;
  6. Diseases of the blood system;
  7. Severe pulmonary hypertension (PAPm ≥ 45mmHg);
  8. Abnormal thyroid function;
  9. Patients with a history of venous thromboembolism, or serious events such as severe bleeding or embolism;
 10. Women who are pregnant or breastfeeding;
 11. Taking or planning to take other oral anticoagulants;
 12. The base INR value is >1.4;
 13. VKORC1, CYP2C9 genotypes are AA, *1/*1;
 14. Secondary valve replacement surgery;
 15. Emergency hospital admission for valve surgery;
 16. Diagnosis of coronary atherosclerotic heart disease;
 17. Severe mental illness, mental disorder ; -